Ranking Invest

Belite Bio, Inc

Segmento: Healthcare Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery of vitamin A to the eye to reduce the accumulation of toxic vitamin A by-products in ocular tissue that is in phase 3 clinical trial. The company is also developing LBS-009, an anti-retinol binding protein 4 oral therapy targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, which is in the preclinical development phase. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.

Indicadores Básicos

Valor de Mercado

$ 2.01 Bi

IVR

0.03

IVR2

-0.05

Índices de Previsibilidade

Faturamento

0.00

Lucro

0.34

Margem

0.00

Índices de Tendência

Faturamento

0.00

Lucro

-10.73

Margem

0.00

Índices de Endividamento

DIV/PAT

0.00

DIV/L4T

0.00

Dívida Líquida

$ -

Patrimônio Líquido

$ 158.07 Mi

L4T

-$ 42.55 Mi

MM4T

0.00%

Dívidas
Dividendos
Cotação: $61.81

Não há dados de histórico de dividendos para exibir.

Gráfico Lucro/Faturamento X Trimestre